Amphix Bio bolsters operations with new hires
May 1, 2024
Amphix Bio has announced the additions of Hussain Sangji, PhD, as Director of Operations and Iwona Maciagiewicz, PhD, as CMC Director. The new full-time hires join Amphix Bio as the company is scaling up production of its supramolecular regenerative therapies, initiating regulatory filings with the FDA, and gearing up for first-in-human clinical trials.
“I am thrilled to welcome Hussain and Iwona to the team at an exciting time for our company,” said Amphix Bio CEO Nick Sather, PhD. “It is critical that we continue our positive momentum in advancing our novel regenerative medicine platform to the clinic, and they each have diverse skill sets that will accelerate that effort.”
Iwona Maciagiewicz (left) and Hussain Sangji (right) pose with Amphix Bio CEO Nick Sather outside the company's Chicago office.
Dr. Sangji most recently worked for the Boston Consulting Group as a Project Leader, where he led business strategy, operations, and regulatory projects for major biopharma and medical technology companies. He previously completed his PhD research with Amphix Bio co-founder Prof. Samuel Stupp, providing him with deep knowledge of the company’s technology. He will support Amphix Bio in product development and operations.
Dr. Maciagiewicz is an expert in synthetic and medicinal organic chemistry and has experience with R&D, current Good Manufacturing Practices (cGMP) protocols, and intellectual property management. She was previously an Invention Manager at Northwestern University’s technology transfer office and has worked at four other biotech and chemistry startups, including one she co-founded.